See the DrugPatentWatch profile for keytruda

Keytruda (pembrolizumab) is a medication used to treat various types of cancer, including melanoma, lung cancer, and classical Hodgkin lymphoma. The FDA approved Keytruda for the treatment of metastatic melanoma in September 2014 [1]. Since then, the FDA has approved Keytruda for additional indications, including:

* Unresectable or metastatic melanoma in September 2014 [1]
* Adjuvant treatment of melanoma in March 2017 [2]
* Recurrent or metastatic cervical cancer in March 2019 [3]
* Classical Hodgkin lymphoma in October 2017 [4]
* Non-small cell lung cancer (NSCLC) in October 2015 [5]
* NSCLC with high PD-L1 expression in October 2015 [5]
* NSCLC with high PD-L1 expression and two or more prior chemotherapy regimens in October 2015 [5]
* Recurrent or metastatic esophageal squamous cell carcinoma in June 2020 [6]
* Recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma in June 2020 [6]
* Recurrent or metastatic esophageal adenocarcinoma in June 2020 [6]

The FDA approval dates mentioned above are based on the available information and may not be exhaustive. For the most up-to-date information on FDA-approved indications and dosages, please consult the FDA's website or consult with a healthcare professional.

Sources:

[1] FDA. (2014, September 4). FDA Approves Merck's Keytruda for Advanced Melanoma. Retrieved from <https://www.fda.gov/news-events/press-announcements/fda-approves-mercks-keytruda-advanced-melanoma>

[2] FDA. (2017, March 24). FDA Approves Merck's Keytruda for Adjuvant Treatment of Melanoma. Retrieved from <https://www.fda.gov/news-events/press-announcements/fda-approves-mercks-keytruda-adjuvant-treatment-melanoma>

[3] FDA. (2019, March 26). FDA Approves Merck's Keytruda for Recurrent or Metastatic Cervical Cancer. Retrieved from <https://www.fda.gov/news-events/press-announcements/fda-approves-mercks-keytruda-recurrent-or-metastatic-cervical-cancer>

[4] FDA. (2017, October 18). FDA Approves Merck's Keytruda for Classical Hodgkin Lymphoma. Retrieved from <https://www.fda.gov/news-events/press-announcements/fda-approves-mercks-keytruda-classical-hodgkin-lymphoma>

[5] FDA. (2015, October 28). FDA Approves Merck's Keytruda for NSCLC. Retrieved from <https://www.fda.gov/news-events/press-announcements/fda-approves-mercks-keytruda-nsclc>

[6] FDA. (2020, June 17). FDA Approves Merck's Keytruda for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma. Retrieved from <https://www.fda.gov/news-events/press-announcements/fda-approves-mercks-keytruda-recurrent-or-metastatic-esophageal-squamous-cell-carcinoma-gastric-or>

DrugPatentWatch.com. (n.d.). Pembrolizumab (Keytruda). Retrieved from <https://www.drugpatentwatch.com/patent/US-9,342,049>